Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1
Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1
复制标题
DOI：
10.1093/infdis/173.3.765
复制
发表时间：
1996-03-01
影响因子：
6.4
通讯作者：
Riley, EM
中科院分区：
文献类型：
--
作者：
Egan, AF;Morris, J;Riley, EM
有效疟疾疫苗的开发依赖于作为保护性免疫应答靶点的抗原的鉴定。免疫流行病学方法已被用于研究针对恶性疟原虫裂殖子表面主要蛋白的特定区域的抗体应答之间的关系。（PfMSP-1（19））和来自西非的2个儿童群体对临床疟疾的耐药性，在考虑到年龄的混杂影响后，在塞拉利昂的儿童中，PfMSP-1的抗体（19）显示出提供了类似于40%的针对临床疟疾的保护。在冈比亚的儿童中，PfMSP-1的表皮生长因子样基序之一的抗体（19）与对临床疟疾和高水平寄生虫血症的抗性强烈相关。
The development of an effective malaria vaccine depends upon identification of antigens that are targets of protective immune responses, An immunoepidemiologic approach has been used to investigate the relationship between antibody responses to a defined region of the major merozoite surface protein of Plasmodium falciparum (PfMSP-1(19)) and resistance to clinical malaria in 2 populations of children from West Africa, After allowing for the confounding effects of age, antibodies to PfMSP-1(19) were shown to provide similar to 40% protection against clinical malaria in children in Sierra Leone, In Gambian children, antibodies to one of the epidermal growth factor-like motifs of PfMSP-1(19) were strongly associated with resistance to both clinical malaria and high levels of parasitemia.